By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) 

245 First Street
Suite 1800
Cambridge  Massachusetts  02142  U.S.A.
Phone: 503-227-0554 Fax: 503-227-0751


Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of rare, infectious and other diseases.

Formerly called Antivirals, Inc.




CEO: Ed Kaye, M.D.


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Sarepta
Employees: 48
Symbol: SRPT


Company News
Sarepta (SRPT)’s Duchene Muscular Dystrophy Drug: Evaluating the Placebo Effect 8/18/2016 8:03:55 PM
Sarepta (SRPT) Stock Surges After Government Website Indicates Firm is Recruiting for Phase III Study 8/4/2016 6:19:23 AM
Sarepta (SRPT) Announces Second Quarter 2016 Financial Results And Recent Corporate Developments 7/20/2016 8:46:08 AM
Sarepta (SRPT)'s Study Period Extension May Help Gain DMD Drug Approval in the Long Run 6/24/2016 6:50:00 AM
Sarepta (SRPT) Announces Common Stock Offering 6/9/2016 8:29:07 AM
Sarepta (SRPT) Surges Yet Again, as the FDA Requests More Data About Duchenne’s Drug 6/7/2016 5:55:29 AM
All Eyes Turn to Sarepta (SRPT) as BioMarin (BMRN) Shutters Its Kyndrisa Duchenne Program 6/1/2016 6:25:05 AM
Approving Sarepta (SRPT)'s DMD Drug Could Force FDA To Get Creative 5/26/2016 7:44:39 AM
Sarepta (SRPT) Rockets After the FDA Delays Ruling on DMD Drug 5/25/2016 5:52:53 AM
Sarepta (SRPT) Who? This DMD Drugmaker Might be a Better Buy for Investors 5/20/2016 6:40:26 AM